AnaptysBio, Inc. (NASDAQ:ANAB) – Stock analysts at Wedbush cut their Q1 2018 EPS estimates for shares of AnaptysBio in a research note issued to investors on Tuesday. Wedbush analyst D. Nierengarten now anticipates that the biotechnology company will earn ($0.56) per share for the quarter, down from their prior estimate of ($0.51). Wedbush also issued estimates for AnaptysBio’s Q2 2018 earnings at ($0.61) EPS, Q3 2018 earnings at ($0.66) EPS, Q4 2018 earnings at ($0.72) EPS, FY2018 earnings at ($2.55) EPS, FY2019 earnings at ($2.95) EPS, FY2020 earnings at ($3.08) EPS and FY2021 earnings at ($1.81) EPS.

Other analysts have also recently issued research reports about the stock. Zacks Investment Research upgraded shares of AnaptysBio from a “hold” rating to a “buy” rating and set a $36.00 price target on the stock in a report on Wednesday, September 13th. Royal Bank Of Canada began coverage on shares of AnaptysBio in a report on Thursday, September 14th. They issued an “outperform” rating and a $40.00 price target on the stock. Stifel Nicolaus reiterated a “buy” rating and issued a $35.00 price target on shares of AnaptysBio in a report on Tuesday, September 12th. Robert W. Baird set a $69.00 price target on shares of AnaptysBio and gave the company a “buy” rating in a report on Wednesday. Finally, JMP Securities lifted their price target on shares of AnaptysBio from $45.00 to $82.00 and gave the company an “outperform” rating in a report on Tuesday. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. AnaptysBio currently has a consensus rating of “Buy” and an average price target of $59.14.

WARNING: “Q1 2018 EPS Estimates for AnaptysBio, Inc. (ANAB) Cut by Analyst” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/13/q1-2018-eps-estimates-for-anaptysbio-inc-anab-cut-by-analyst.html.

AnaptysBio (NASDAQ ANAB) traded down 1.68% during midday trading on Friday, hitting $69.61. 831,249 shares of the stock were exchanged. AnaptysBio has a 1-year low of $15.17 and a 1-year high of $74.00. The company’s 50 day moving average is $38.75 and its 200-day moving average is $38.75. The stock’s market cap is $1.42 billion.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Thursday, August 10th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.29. The business had revenue of $7.00 million for the quarter, compared to the consensus estimate of $3.45 million.

Several hedge funds have recently made changes to their positions in the company. Perceptive Advisors LLC bought a new stake in shares of AnaptysBio during the 1st quarter valued at $24,474,000. Artal Group S.A. boosted its stake in AnaptysBio by 459.4% in the 2nd quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock worth $5,983,000 after purchasing an additional 205,310 shares in the last quarter. Marshall Wace North America L.P. bought a new position in AnaptysBio in the 1st quarter worth about $6,924,000. MARSHALL WACE ASIA Ltd bought a new position in AnaptysBio in the 1st quarter worth about $6,924,000. Finally, Vanguard Group Inc. boosted its stake in AnaptysBio by 22.6% in the 2nd quarter. Vanguard Group Inc. now owns 206,031 shares of the biotechnology company’s stock worth $4,931,000 after purchasing an additional 37,932 shares in the last quarter. Hedge funds and other institutional investors own 71.35% of the company’s stock.

In other news, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the business’s stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $24.35, for a total transaction of $901,924.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder Holdings A/S Novo sold 356,300 shares of the business’s stock in a transaction on Monday, August 21st. The shares were sold at an average price of $21.10, for a total transaction of $7,517,930.00. Following the sale, the insider now owns 1,936,604 shares in the company, valued at approximately $40,862,344.40. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,133,940 shares of company stock worth $24,223,316.

AnaptysBio Company Profile

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Earnings History and Estimates for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.